The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension

British Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 575-582

  Lefebvre, Jean ^a,b   Poirier, Luc ^a   Poirier, Paul ^b,c   Turgeon, Jacques ^d   Lacourciere, Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CYP2D6; Hypertension; Nebivolol

Indexed keywords

CYTOCHROME P450 2D6; NEBIVOLOL;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ENANTIOSELECTIVITY; ESSENTIAL HYPERTENSION; EXTERNAL OTITIS; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HEART RATE; HUMAN; HYPERKINESIA; HYPESTHESIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERIPHERAL EDEMA; PHENOTYPE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SINUSITIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; CYTOCHROME P-450 CYP2D6; ETHANOLAMINES; FEMALE; GENOTYPE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34247366467     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02796.x     Document Type: Article

References (30)

1. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta1-adrenergic antagonist. J Cardiovasc Pharmacol 1988 11 : 552 63.
2. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991 17 : 964 9.
3. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995 274 : 1067 71.
4. Xhonneux R, Wouters L, Reneman RS, Janssen PA. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol 1990 181 : 261 5.
5. Cockcroft J. Nebivolol: a review. Expert Opin Pharmacother 2004 5 : 893 9.
6. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002 62 : 265 84.
7. Ritter JM, Ferro A, Chowienczyk PJ. Relation between beta-adrenoceptor stimulation and nitric oxide synthesis in vascular control. Eur J Clin Pharmacol 2006 62 (Suppl. 13 109 13.
8. Lacourcière Y, Poirier L, Lefebvre J, Archambault F, Cléroux J. Comparative assessment of antihypertensive efficacy of DL-nebivolol and d-nebivolol in patients with confirmed mild to moderate hypertension. J Cardiovasc Pharmacol 1995 25 : 619 24.
9. Van Peer A, Snoeck E, Woestenborghs R. Clinical pharmacokinetics of nebivolol. A review. Drug Invest 1991 3 (Suppl. 1 25 30.
10. Janssens WJ, Snoeck E. Pharmacology and Pharmacokinetics of Nebivolol. Symposium on Endothelium in Hypertension. New Therapeutic Trends. Berlin, Germany. 1 March 1997. 10 3.
11. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 369 : 23 37.
12. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf 1997 16 : 355 65.
13. Ioannidis JP, Lau J. Improving safety reporting from randomised trials. Drug Saf 2002 25 : 77 84.
14. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990 12 : 97 104.
15. Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996 6 : 417 21.
16. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995 5 : 215 23.
17. Woestenborghs R, Guens I, Lenoir H, Janssen C, Heykants J. On the selectivity of some recently developed RIA's. In : Analysis of Drugs and Metabolites, Including Anti-Infective Agents, Reid E, Wilson I. Cambridge : Royal Society of Chemistry 1990 : 241 6.
18. Cheymol G, Woestenborghs E, Snoeck E, Ianucci R, Le Moing JP, Naditch L, Levron JC, Poirier JM. Pharmacokinetics study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Pharmacol 1997 51 : 493 8.
19. Lacourcière Y, Lefebvre J, Poirier L, Archambaul F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994 7 : 137 45.
20. Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993 21 : 856 62.
21. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J, Werner D, Eschenhagen T. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002 72 : 429 37.
22. Eichorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997 79 : 794 8.
23. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van Gorsel E, Heemskerk JW, Egbrink MG, van Breda E, Reneman RS, van Der Zee R. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release. Circulation 2000 102 : 677 84.
24. Kakoki M, Hirata Y, Hayakawa H, Nishimatsu H, Suzuki Y, Nagata D, Suzuki E, Kikuchi K, Nagano T, Omata M. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999 33 (1 Part 2 467 71.
25. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999 48 : 460 3.
26. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994 38 : 199 204.
27. Kubli S, Feihl F, Waeber B. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation. Clin Pharmacol Ther 2001 69 : 238 44.
28. Tzemo N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001 104 : 511 4.
29. Kendall MJ, John VA, Quarterman CP, Welling PG. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow release metoprolol. Eur J Clin Pharmacol 1980 17 : 87 92.
30. Nadelmann J, Frishman WH. Clinical use of beta-adrenoceptor blockade in systemic hypertension. Drugs 1990 39 : 862 76.